Bristol-Myers Squibb Co (BMY) has declared a quarterly dividend of $0.62 per share, underscoring its commitment to returning value to shareholders. This dividend will be payable to shareholders of record on November 2, 2025, following the ex-dividend date of October 2, 2025.
The company’s current dividend yield stands at 5.41%, reflecting the annual income relative to its stock price. Bristol-Myers Squibb has a strong history of regular dividend payments, which provide consistent income for investors.
With a market capitalization of $92.4 billion and a price-to-earnings ratio of 15.29, the company continues to engage in the discovery and development of innovative biopharmaceutical products. Its growth portfolio includes key medications such as Opdivo, Yervoy, and Eliquis, among others. This robust pipeline supports its ability to generate cash flow, which is critical for sustaining dividend payments.
Investors are encouraged to consider the company’s dividend history, payout ratio, and overall financial health when assessing the sustainability of its dividend strategy. Upcoming earnings are anticipated on July 30, 2026, with an estimated EPS of $1.60 and revenue of $11.7 billion.